1999 ANNUAL MEETING

The AACR’s Annual Meeting is one of the largest and most important annual gatherings of scientists engaged in cancer research worldwide. The next Annual Meeting will take place in Philadelphia, PA, April 10–14, 1999. The Chairperson of the Annual Meeting is Waun Ki Hong of the UT-M.D. Anderson Cancer Center. Co-Chairpersons are Carol W. Greider, Johns Hopkins University School of Medicine; Joseph F. Fraumeni, Jr., National Cancer Institute; and Leroy Fong Liu, Robert Wood Johnson Medical School.

The Program Committee has invited outstanding scientists in the field to organize plenary sessions, symposia, scientific forums, and meet-the-expert sunrise sessions. It has also reviewed nearly 5,000 proffered papers submitted by members of the cancer research community and has scheduled acceptable ones in minisymposia, poster discussion sessions, and poster sessions. The deadline for submission of abstracts was November 6, 1998. Further program information can be found on the AACR’s website (http://www.aacr.org).

FUTURE ANNUAL MEETINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH

2000 April 1–5, San Francisco, CA
2001 March 24–28, New Orleans, LA
2002 April 6–10, San Francisco, CA

WORKSHOP ON PATHOBIOLOGY OF CANCER

The AACR will sponsor a workshop entitled “Pathobiology of Cancer” at the Keystone Center in Keystone, Colorado, from July 18–25, 1999. This workshop is supported by a generous grant from the National Cancer Institute that will offset the costs of registration, housing, and meals for approximately 100 graduate students and postdoctoral fellows engaged in basic cancer research (including epidemiological studies). A limited number of senior scientists will also be admitted to the workshop upon payment of a registration fee.

This intensive, one-week workshop will provide participants with a background in cancer biology, pathology, and cancer-related disciplines. The program consists of 28 hours of laboratory sessions, 10 hours of lectures, and 4 hours of poster sessions. The Course Director for 1999 is Dr. Frederic M. Waldman of the University of California at San Francisco; the Deputy Director is Dr. Ann D. Thor of Northwestern University. They will direct a faculty of outstanding cancer researchers who will head the various laboratory sections and present lectures on recent advances in the field of histopathobiology of cancer and other appropriate scientific disciplines. Information and application forms were mailed to AACR members in February. Nonmembers should request information and brochures from the AACR office.

WORKSHOP ON MOLECULAR BIOLOGY IN CLINICAL ONCIOLOGY

The AACR will sponsor an intensive, one-week summer workshop on molecular biology designed for clinical oncolgists in training and in their early academic careers. The workshop will take place at the Given Biomedical Institute in Aspen, Colorado, from July 2–8, 1999. Recent advances in molecular biology are becoming more and more relevant to the diagnosis, therapy, and management of cancer patients. The workshop will give clinical oncologists the opportunity to interact closely in an informal setting with experts in the field of molecular biology, learn their language and laboratory techniques, better understand relevant literature, and communicate more effectively with their basic science colleagues.

Michael B. Kastan of the Johns Hopkins University School of Medicine, L. Michael Glode of the University of Colorado School of Medicine, and Jennifer A. Pietenpol of the Vanderbilt University School of Medicine will serve as chairpersons of the workshop and will invite a distinguished faculty to direct five 2½-hour laboratory sessions and deliver 20 hours of lectures. Generous support from the National Cancer Institute will provide funding for the registration fees and hotel accommodations of 65 physicians in training and oncology fellows. Ten senior clinical oncolgists will also be able to attend the workshop upon payment of a registration fee.

Information and application forms were mailed to AACR members in January. Nonmembers should request brochures from the AACR office.

WORKSHOP ON METHODS IN CLINICAL CANCER RESEARCH

The AACR and the American Society of Clinical Oncology (ASCO) will sponsor a six-day summer workshop on clinical research methods designed for both oncologists in training and senior investigators. The workshop will take place at the Vail Cascade Hotel and Club in Vail, Colorado, from July 31–August 6, 1999. The overall goal of the workshop will be to educate clinical scientists in methods for clinical research and to encourage better clinical trial design so that new cancer treatments can be introduced more rapidly into general medical practice. Major support for this program is provided by the National Cancer Institute. Support is also provided by Bristol-Myers Squibb, Amgen, Hoechst Marion Roussel, and Searle. Funds will be available to offset the registration fees and housing and subsistence expenses for 75 clinical trainees to attend the workshop. In addition, 25 clinical investigators at the level of junior faculty will be accepted to the workshop; their registration fees will be waived, and some travel support will be available.

The Workshop Organizing Committee is chaired by Drs. Daniel D. Von Hoff, Charles A. Coltman, Jr., and Gary M. Clark. They will invite and select a distinguished faculty that will deliver over 20 hours of lectures on a variety of topics in the field and direct several small-group discussion sessions in which 15–20 participants can review important aspects of the design of clinical trials. In addition, each participant will be responsible for the preparation of an actual protocol for a clinical trial while attending the workshop. Groups of six to eight students will meet with two assigned faculty members on several occasions during the week to review intermediate drafts of these protocols.

Information and application forms were mailed to AACR and ASCO members in February. Nonmembers should request brochures from the AACR office.

AACR SPECIAL CONFERENCES IN CANCER RESEARCH

A number of meetings are now being organized in the AACR’s series of smaller scientific meetings. Following are the topics, dates, locations, and program committees for these meetings. When full details of each meeting are available, AACR members will be the first to receive complete brochures and application forms for participation in these important conferences. Nonmembers may receive this information by sending their names and addresses to Meetings Mailing List, American Association for Cancer Research, Public Ledger Building, 150 South Independence Mall West, Suite 826, Philadelphia, PA 19106-3483. Up-to-date program information is also available via the Internet at the AACR’s website (http://www.aacr.org/confncr.html).

MOLECULAR ASPECTS OF METASTASIS

September 22–26, 1999
Snowmass Village Resort, Snowmass, CO

Chairpersons
Ruth J. Muschel, Philadelphia, PA
Patricia S. Steeg, Bethesda, MD
THE MOLECULAR AND GENETIC BASIS OF CHEMOPREVENTION AND EARLY DETECTION OF CANCER
October 6–10, 1999
Sheraton Bal Harbour Beach Resort, Bal Harbour, FL

Chairpersons
David Sidransky, Baltimore, MD
Frank L. Meyskens, Jr., Orange, CA

GENETIC AND FUNCTIONAL CONSEQUENCES OF CELL CYCLE ALTERATIONS IN CANCER
October 20–24, 1999
Sheraton San Diego Hotel & Marina, San Diego, CA

Chairpersons
Steven I. Reed, La Jolla, CA
Joan V. Ruderman, Boston, MA

MOLECULAR TARGETS AND CANCER THERAPEUTICS: DISCOVERY, DEVELOPMENT, AND CLINICAL VALIDATION
Co-sponsored by the National Cancer Institute and the European Organisation for Research and Treatment of Cancer
November 16–19, 1999
Washington Hilton Hotel, Washington, DC

Chairpersons:
Daniel D. Von Hoff, San Antonio, TX
Robert E. Wittle, Bethesda, MD
Jean-Claude Horiot, Dijon, France

DNA REPAIR DEFECTS
January 14–18, 2000
San Diego Hilton Beach & Tennis Resort, San Diego, CA

Chairperson
Richard D. Kolodner, La Jolla, CA

DISRUPTED TRANSCRIPTION FACTORS IN CANCER
January 26–30, 2000
Marriott Laguna Cliffs Resort, Dana Point, CA

Chairpersons
Peter K. Vogt, La Jolla, CA
Frank J. Rauscher, III, Philadelphia, PA

PROGRAMMED CELL DEATH: CLINICAL APPLICATIONS
February–March 2000
Location to be announced

Chairpersons
John C. Reed, La Jolla, CA
Junying Yuan, Charlestown, MA

RECENT DEATHS

We regret to report the deaths of Drs. Eric Archimbaud of Lyon, France; Maurizio Soma of Milan, Italy; and Charles Gordon Zubrod of Chevy Chase, MD. Drs. Archimbaud and Soma were Corresponding Members and Dr. Zubrod was an Emeritus Member of the American Association for Cancer Research.

CALENDAR OF EVENTS

Antibody Production & Downstream Processing, March 17–19, 1999, The Westin Horton Plaza Hotel, San Diego, CA. Contact: IBC USA Conferences, 225 Turnpike Road, Southborough, MA 01722. Phone: (508) 481-6400; Fax: (508) 481-4473; Email: reg@ibcusa.com.

Human Genetics and Human Cancer, April 28–30, 1999, New York, NY. Contact: Memorial Sloan Kettering Cancer Center, Office of Continuing Medical Education, 1245 York Avenue, Box 31, New York, NY 10021. Phone: (212) 639-6754; Fax: (212) 717-3140.

Oncology Nursing Society 24th Annual Congress: Embracing New Traditions, April 28–May 1, 1999, Atlanta, GA. Contact: ONS National Office, Meeting Services Team, 501 Holiday Drive, Pittsburgh, PA 15220-2749. Phone: (412) 921-7373, ext. 553; Fax: (412) 921-6565; E-mail: meeting@ons.org.

Third International Conference on Human Herpesviruses 6, 7, and 8, May 13–15, 1999, Clearwater Beach, FL. Contact: Dr. Peter Medveczky, University of South Florida, Department of Medical Microbiology, Tampa, FL 33612-4799. Phone: (813) 974-3281; Fax: (813) 974-4151; E-mail: pmedvecz@com1.med.usf.edu.


International Conference on Diet and Prevention of Cancer, May 28–June 2, 1999, Tampere, Finland. Contact: Congress Secretariat, ICDFC’99, P.O. Box 151, 00141 Helsinki, Finland. Phone: (35) 8 9 175 355; Fax: (35) 8 9 170 122; E-mail: 74161.1110@Compuserve.com.

Tenth National Meeting for State Cancer Pain Initiatives: Building a Pain Management Community, June 3–5, 1999, Double Tree Inn, Salt Lake City, UT. Contact: Sarah Aslakson, Continuing Medical Education, 2715 Marshall Court, Madison, WI 53705. Phone: (608) 263-2856; Fax: (608) 262-8421; E-mail: aslakson@facstaff.wisc.edu.

2nd Annual Meeting of The American Society of Gene Therapy, June 9–13, 1999, Marriott Wardman Park Hotel, Washington, DC. Contact: ASGT Registration Manager, 6900 Grove Road, Thorofare, NJ 08086. Phone: (609) 848-1000; Fax: (609) 848-5274; Email: ASGT@slackinc.com; Website: http://www.asgt.org.

4th Cancer Research Campaign Beatson International Cancer Conference: Invasion and Metastasis, June 27–30, 1999, Glasgow, Scotland. Contact: Tricia Allister, Beatson Institute for Cancer Research, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, United Kingdom. Phone: 44 141 942 0855; Fax: 44 141 942 6521; Email: twheeler@beatson.gla.ac.uk; Website: http://www.Beatson.gla.ac.uk.

ISCD ‘99: 11th International Symposium on Chiral Discrimination, July 25–28, 1999, Chicago, IL. Contact: Janet Cunningham, Barr Enterprises, P.O. Box 279, Walkersville, MD 21793. Phone: (301) 898-3772; Fax: (301) 898-5596; Website: http://www.CHIRAL.com.
Errata


In the article by L. R. Bailey et al., which appeared in the November 15, 1998 issue of Cancer Research (pp. 5038–5041), Materials and Methods, Paragraph 2, Lines 5–6., “. . . primer 2, 5’-GCC TCT TGC TTC TTA TTG GCA . . .” should read “. . . primer 2, 5’-GCC CAC TGA AAA AAT CAT CAC TCT GCT GGT CAG GTG C.” The primer contains a mutated nucleotide (underlined) to introduce a Cac8l site in order to reveal the polymorphism in codon 453.

In the article by L. Bubendorf et al., which appeared in the February 15, 1999 issue of Cancer Research (pp. 803–806), Footnote 3 incorrectly states that Dr. Guido Sauter is supported by Clinical Cancer Foundation, Basel, Switzerland. Dr. Thomas C. Gasser is the actual recipient of this support.

ISPPP ’99: 19th International Symposium on the Separation of Proteins, Peptides and Polynucleotides, October 31–November 3, 1999, Delray Beach, FL. Contact: Janet Cunningham, Barr Enterprises, P.O. Box 279, Walkersville, MD 21793. Phone: (301) 898-3772; Fax: (301) 898-5596; Website: http://www.ZORBAX.com/isppp.

Third International Symposium on the Role of Soy in Preventing and Treating Chronic Disease, October 31–November 3, 1999, Omni Sheraton Hotel, Washington, DC. Contact: Mindy McDaniel Cain, Symposium Management, P.O. Box 3489, Champaign, IL 61826-3489. Phone: (217) 359-2344; Fax: (217) 351-8091; Email: meetings@aocs.org; Website: http://www.aocs.org/soysymp.htm.

5th International Symposium on Insulin-like Growth Factors, October 31–November 4, 1999, Brighton, United Kingdom. Contact: Janet Crompton, 29 North Road, St. Andrews, Bristol BS6 5AD, United Kingdom. Phone: (44) 117 924 8160; Fax: (44) 117 924 1208; Email: janetcrompton@compuserve.com.

6th Hong Kong International Cancer Congress, November 14–17, 1999, Hong Kong Convention and Exhibition Centre. Contact: 6th HKICC Congress Secretariat, Department of Surgery, University of Hong Kong Medical Centre, Queen Mary Hospital, Hong Kong. Phone: (852) 2818-0232/(852) 2855-4235; Fax: (852) 2818-1186; Email: mededcon@hku.hk.

First International Conference on Translational Research and Pre-Clinical Strategies in Radio-Oncology, March 5–8, 2000, Palazzo dei Congressi-Center, Lugano Switzerland. Contact: Dr. Jacques Bernier, Cancer Research, University of Hong Kong, Sand Giovanni Hospital, CH-6504 Bellinzona, Switzerland. Phone: 41 91 820 91 57; Fax: 41 91 820 90 44; jbemriner@cscs.ch; Website: http://www.osg.ch/ictr2000.html.

7th European Workshop on Pituitary Adenomas, September 10–13, 2000, Oxford, United Kingdom. Contact: Janet Crompton, 29 North Road, St. Andrews, Bristol BS6 5AD, United Kingdom. Phone: (44) 117 924 8160; Fax: (44) 117 924 1208; Email: janetcrompton@compuserve.com.
Correction

In the article by S. Berg et al., which appeared in the October 15, 1995 issue of Cancer Research (pp. 4606–4610), we previously reported the plasma and cerebrospinal fluid (CSF) pharmacokinetics of O6-benzylguanine (O6BG) and its active metabolite O6-benzyl-8-oxoguanine (8-oxo-O6BG) after intravenous administration of 200 mg/m2 of O6BG in the nonhuman primate. O6BG irreversibly inactivates the DNA repair protein alkylguanine-alkyltransferase, thus increasing cell sensitivity to agents that alkylate the O6-position of guanine, such as carmustine, lomustine, procarbazine, and temozolomide. After intravenous administration of O6BG, both O6BG and its active metabolite, 8-oxo-O6BG, are detectable in plasma and CSF. We would like to correct an error we discovered in our calculation of the CSF concentrations of 8-oxo-O6BG. The correct ratio of CSF:plasma area under the concentration-time curve for 8-oxo-O6BG is 1.7 ± 0.7%. The peak concentration in CSF of O6BG is 2.4 ± 0.6 μM and of 8-oxo-O6BG is 2.2 ± 0.6 μM. The corrected version of Table 2 from the original paper is included below. This change does not affect any other aspect of the paper.

Stacey Berg
Texas Children’s Cancer Center
Baylor College of Medicine
Houston, TX 77030

Frank Balis
Pediatric Branch
National Cancer Institute
Bethesda, MD 20892

Table 2. Plasma and CSF exposure and CSF half-life of O6-benzylguanine and its active metabolite, O6-benzyl-8-oxoguanine

<table>
<thead>
<tr>
<th>Animal</th>
<th>O6-Benzylguanine</th>
<th></th>
<th></th>
<th>O6-Benzyl-8-oxoguanine</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AUCplasma (µMh)</td>
<td>AUCCSF (µMh)</td>
<td>t1/2 CSF (hr)</td>
<td>CSF:plasma (%)</td>
<td>AUCplasma (µMh)</td>
<td>AUCCSF (µMh)</td>
</tr>
<tr>
<td>1</td>
<td>260</td>
<td>11.1</td>
<td>1.8</td>
<td>4.2</td>
<td>3410</td>
<td>37</td>
</tr>
<tr>
<td>2</td>
<td>210</td>
<td>8.1</td>
<td>2.0</td>
<td>3.8</td>
<td>2080</td>
<td>32</td>
</tr>
<tr>
<td>3</td>
<td>260</td>
<td>8.1</td>
<td>1.6</td>
<td>5.0</td>
<td>1780</td>
<td>45</td>
</tr>
<tr>
<td>Mean</td>
<td>210</td>
<td>9.1</td>
<td>1.8</td>
<td>4.3</td>
<td>2420</td>
<td>38</td>
</tr>
<tr>
<td>S.D.</td>
<td>50</td>
<td>1.8</td>
<td>0.2</td>
<td>0.6</td>
<td>870</td>
<td>7</td>
</tr>
</tbody>
</table>